Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × obatoclax × Clear all
NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT00918931 2011-11-04

Obatoclax for Systemic Mastocytosis

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 2 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡